Jim Cramer Says “CRISPR Can Either Triple or Do Nothing”

CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the stocks that Jim Cramer weighed in on. When a caller inquired about the company, Cramer stated:

“You see, here’s the deal: There’s so many stocks that are going up. People don’t even like think, it’s like, oh man, boy, I forgot about CRISPR. Well, I haven’t. I think CRISPR is a terrific, terrific, but speculative situation, and I think you should be able to speculate. I think CRISPR, look, CRISPR can either triple or do nothing. That’s not a bad ratio.”

Photo by jason briscoe on Unsplash

CRISPR (NASDAQ:CRSP) develops gene-based medicines using its CRISPR/Cas9 platform, which targets a range of diseases, including hemoglobinopathies, cancer, cardiovascular conditions, and type 1 diabetes. The company’s lead therapy is focused on gene-edited treatment for sickle cell disease and beta-thalassemia. Cramer mentioned the company in a January episode and said:

“You know, I want to own, I want to own CRISPR because I keep seeing their name come up and all the science papers that I read and I read quite a bit of them, but boy, the stock’s been a tough own. Let’s put some away and then if it goes lower, we’ll buy more. But I, I understand. How could that company keep losing money like this? It is just, it’s Moderna-like… in the money they throw in the chimney.”

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.